๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Guangzhou
Clinical trial register · China

Clinical Trials in Guangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University451 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University181 Nanfang Hospital, Southern Medical University138 AstraZeneca133 Guangdong Provincial People's Hospital81
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Guangzhou

3318 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Incidence of Glaucoma-related Adverse Events in Pediatric Secondary Intraocular Lens Implantation
NCT05136950Lens Implantation, Intraocular
Zhongshan Ophthalmic Center, Sun Yat-sen University
Not applicable
228
Guangzhou
2021-12-14
Active, closed
Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)
NCT04954859Hepatitis B
DrugBepirovirsen
GlaxoSmithKline
Phase 2
360
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Kunming, Liuzhou
2021-12-14
Active, closed
A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
NCT05070858Generalized Myasthenia Gravis
DrugsCemdisiran·Pozelimab
Regeneron Pharmaceuticals
Phase 3
288
Beijing, Fuzhou, Guangdong, Guangzhou, Shenzhen, Haikou, Wuhan, Changsha
2021-12-14
Active, closed
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
NCT05116189Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms
DrugsPembrolizumab·Paclitaxel·Bevacizumab
Merck Sharp & Dohme LLC
Phase 3
643
Hefei, Beijing, Fuzhou, Lanzhou, Guangzhou, Zhanjiang, Nanning, Haikou
2021-12-13
Recruiting
Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms
NCT05000892Salivary Gland Malignant Neoplasms, Salivary Gland Tumors
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
15
Guangzhou
2021-12-10
Recruiting
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
NCT04892173Carcinoma, Squamous Cell
DrugsJNJ-90301900·Pemetrexed
Johnson & Johnson Enterprise Innovation Inc.
Phase 3
500
Bengbu, Changsha, Chengdu, Dongguan, Fuzhou, Guangzhou, Jinan, Linyi
2021-12-10
Active, closed
Surufatinib in Patients With Osteosarcoma and Soft Tissue Sarcoma
NCT05106777Sarcoma
DrugSurufatinib
Sun Yat-sen University
Phase 2
47
Guangzhou
2021-12-10
Recruiting
A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
NCT05077904Stereotypical Prolonged Seizures
DrugStaccato alprazolam
UCB Biopharma SRL
Phase 3
350
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Kunming
2021-12-07
Active, closed
Long-term Efficacy and Safety Study of GV-971
NCT05181475Alzheimer Disease
DrugSodium Oligomannate
Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
Phase 4
800
Beijing, Chongqing, Lanzhou, Foshan, Guangzhou, Shenzhen, Guiyang, Baoding
2021-12-07
Active, closed
SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.
NCT05020457Non Small Cell Lung Cancer
DrugsAP·SI-B001·TP·Paclitaxel
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
69
Chongqing, Guangzhou, Guilin, Jinan, Taizhou
2021-12-07
Active, closed
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
NCT05152147Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
DrugsZanidatamab·Trastuzumab·Oxaliplatin·Capecitabine
Jazz Pharmaceuticals
Phase 3
920
Beijing, Bengbu, Changsha, Changzhi, Changzhou, Chengdu, Fuzhou, Guangzhou
2021-12-02
Active, closed
An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)
NCT05112965Neoplasms
DrugsEnzalutamide·Atezolizumab·Pemetrexed·Paclitaxel
Hoffmann-La Roche
Phase 3
49
Guangzhou, Harbin, Wuhan, Jinan, Hangzhou, Beijing, Changchun, Changsha
2021-12-01
Recruiting
The Value of Monitoring Circulating Cell DNA (ctDNA) in Pediatric Lymphoma: A Prospective, Multicenter Clinical Study
NCT04957901Lymphoma
Sun Yat-sen University
Observational
60
Guangzhou
2021-12-01
Recruiting
Minocycline for Chronic Autoimmune Uveitis
NCT05474729Minocycline, Uveitis, Retinal Degeneration
DrugMinocycline
Sun Yat-sen University
Phase 1/2
10
Guangzhou
2021-12-01
Recruiting
Correlation Between the Changes of Retinal Structure and Function and Ischemic Stroke
NCT05281887Ischemic Stroke
Guangdong Provincial People's Hospital
Observational
120
Guangzhou
2021-12-01
Recruiting
Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers
NCT05194878Colon Cancer Stage II, Colon Cancer Stage III
Sun Yat-sen University
Phase 3
840
Guangzhou
2021-12-01
Active, closed
PREvention of Intrauterine Adhesion After Adhesiolysis With Novel Tri-block deGradable Polymer Film.
NCT04963179Asherman Syndrome, Intrauterine Adhesion
Womed
Not applicable
160
Guangzhou, Hangzhou, Shanghai
2021-11-29
Recruiting
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
NCT05194982Locally Advanced or Metastatic Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
570
Chongqing, Guangzhou, Wuhan, Changsha, Shanghai, Taiyuan
2021-11-29
Active, closed
A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer
NCT05160545Breast Cancer
DrugGNC-035
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
36
Bengbu, Dongguan, Guangzhou, Changsha, Chengdu
2021-11-26
Active, closed
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
NCT05030428Atherosclerotic Cardiovascular Disease
DrugInclisiran sodium
Novartis Pharmaceuticals
Phase 3
17,004
Beijing, Foshan, Guangzhou, Nanning, Harbin, Jingzhou, Wuhan, Changsha
2021-11-23
Active, closed
A Study of LP-128 Capsules in Healthy Subjects
NCT05130567Chronic Hepatitis b
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 1
104
Guangzhou
2021-11-19
Active, closed
Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas
NCT04924608Neurofibromatosis 1, Plexiform Neurofibroma (PN)
DrugSelumetinib
AstraZeneca
Phase 3
145
Beijing, Guangzhou, Shenyang
2021-11-19
Active, closed
Pediatric Spinal Muscular Atrophy (SMA) China Registry
NCT05042921Muscular Atrophy, Spinal
Biogen
Observational
600
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shenzhen, Nanning
2021-11-18
Recruiting
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
NCT05145127Hemophilia A, Hemophilia B
Pfizer
Phase 3
245
Guangzhou, Guiyang, Wuhan, Nanchang, Tianjin, Beijing
2021-11-17
Active, closed
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
NCT04988295Carcinoma, Non-Small-Cell Lung
DrugsLazertinib·Amivantamab·Pemetrexed·Carboplatin
Janssen Research & Development, LLC
Phase 3
776
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Huizhou
2021-11-17
Recruiting
Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
NCT05024214Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma
DrugsSunitinib·Envafolimab·Lenvatinib
3D Medicines (Sichuan) Co., Ltd.
Phase 1/2
170
Bengbu, Beijing, Fuzhou, Xiamen, Dongguan, Guangzhou, Zhuhai, Haerbin
2021-11-15
Recruiting
Effects of Music Therapy on Psychological States Among Cancer Patients Undergoing MRI Scans and a Relevant Mediator
NCT06282887Psycho-Oncology
Guangzhou Concord Cancer Center
Not applicable
80
Guangzhou
2021-11-09
Recruiting
Targeted Optical Biopsy for Local Rectal Scars in Rectal Cancer Patients After Neoadjuvant Chemoradiotherapy
NCT05316103Rectal Cancer
Nanfang Hospital, Southern Medical University
Not applicable
68
Guangzhou
2021-11-04
Recruiting
Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
NCT05187338Lung Cancer, Liver Cancer, Colorectal Cancer, Pancreas Cancer
DrugsIpilimumab·Durvalumab·Pembrolizumab
Second Affiliated Hospital of Guangzhou Medical University
Phase 1/2
100
Guangzhou
2021-11-01
Recruiting
Comparison of Posterior Continuous Curvilinear Capsulorhexis With or Without Anterior Vitrectomy
NCT05136209Congenital Cataract
Sun Yat-sen University
Not applicable
50
Guangzhou
2021-11-01
Active, closed
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
NCT05048797Locally Advanced or Metastatic Non-Small Cell Lung Cancer
DrugsTrastuzumab deruxtecan·Pemetrexed·Cisplatin·Carboplatin
AstraZeneca
Phase 3
454
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan
2021-10-28
Active, closed
A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma
NCT04712097Relapsed or Refractory Follicular Lymphoma
DrugsMosunetuzumab·Lenalidomide·Rituximab
Hoffmann-La Roche
Phase 3
478
Beijing, Changchun, Guangzhou, Harbin, Nanchang, Nanjing, Shanghai, Tianjin
2021-10-27
Active, closed
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
NCT05113251Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer
DrugsPertuzumab·Trastuzumab deruxtecan·Doxorubicin·Trastuzumab
AstraZeneca
Phase 3
927
Beijing, Changsha, Chongqing, Guangzhou, Kunming, Nanning, Qingdao, Shanghai
2021-10-25
Active, closed
A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer
NCT04958239Neoplasms
DrugsEzabenlimab·Pembrolizumab
Boehringer Ingelheim
Phase 1
151
Bengbu, Changsha, Fuzhou, Guangzhou, Wuhan
2021-10-18
Recruiting
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
NCT05123482Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer
DrugsPalacaparib·Saruparib·Rilvegostomig
AstraZeneca
Phase 1/2
460
Beijing, Changsha, Chongqing, Guangzhou, Kunming, Shandong
2021-10-18
Recruiting
Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN)
NCT05044117Head and Neck Squamous Cell Carcinoma
DrugCapecitabine
Sun Yat-sen University
Phase 3
220
Guangzhou
2021-10-18
Active, closed
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
NCT05104866Breast Cancer
DrugsVinorelbine·Dato-DXd·Eribulin·Capecitabine
AstraZeneca
Phase 3
732
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou
2021-10-18
Active, closed
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05083169Multiple Myeloma
DrugsTeclistamab·Bortezomib·Pomalidomide·Daratumumab
Janssen Research & Development, LLC
Phase 3
587
Beijing, Changchun, Changshashi, Chaoyang District, Chengdu, Fuzhou, Guangzhou, Hangzhou
2021-10-14
Active, closed
A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010)
NCT05030506Renal Cell Carcinoma
DrugsBelzutifan·Lenvatinib·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 1
45
Beijing, Guangzhou, Nanjing, Tianjin, Hangzhou
2021-10-13
Active, closed
Study of Sacituzumab Govitecan in Patients With Solid Tumor
NCT05119907Solid Tumor
DrugSacituzumab Govitecan
Gilead Sciences
Phase 2
53
Beijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Nanjing
2021-10-12
Active, closed
A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU
NCT05485948Polycythemia Vera
DrugRopeginterferon alfa-2b
PharmaEssentia
Phase 2
49
Beijing, Changsha, Chongqing, Guangzhou, Hefei, Shanghai, Shenzhen, Suzhou
2021-10-08
Active, closed
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
DrugsAsciminib·Bosutinib·Nilotinib·Dasatinib
Novartis Pharmaceuticals
Phase 3
405
Guangzhou, Shenzhen, Zhengzhou, Wuhan, Nanjing, Suzhou, Xian, Chengdu
2021-10-06
Recruiting
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
NCT05020236Multiple Myeloma
DrugsElranatamab·Pomalidomide·Daratumumab·Dexamethasone
Pfizer
Phase 3
893
Beijing, Fuzhou, Guangzhou, Shenzhen, Shijiazhuang, Zhengzhou, Wuhan, Nanjing
2021-10-04
Active, closed
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
NCT04975308Breast Neoplasms, Neoplasm Metastasis
DrugsImlunestrant·Exemestane·Abemaciclib·Fulvestrant
Eli Lilly and Company
Phase 3
874
Bengbu, Beijing, Fuzhou, Guangzhou, Jiangmen, Shenzhen, Zhanjiang, Zhongshan
2021-10-04
Active, closed
Robotic-Assisted vs. Endoscopic-Assisted Sentinel Lymph Node Biopsy in Breast Cancer
NCT07741734Breast Neoplasms
Guangzhou Women and Children's Medical Center
Observational
150
Guangzhou
2021-10-01
Recruiting
Afterload Mismatch Predictive modLE for Transcatheter Edge-to-Edge Repair (AMPLE-TEER)
NCT07019935Mitral Insufficiency
Sun Yat-sen University
Observational
1,000
Guangzhou
2021-10-01
Active, closed
Robotic-Assisted Versus Endoscopic-Assisted Axillary Lymph Node Dissection in Breast Cancer
NCT07693361Breast Neoplasms
Guangzhou Women and Children's Medical Center
Observational
127
Foshan, Guangzhou
2021-10-01
Active, closed
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
NCT04603807Carcinoma, Non-Small-Cell Lung
DrugsEntrectinib·Crizotinib
Hoffmann-La Roche
Phase 3
217
Changchun, Changsha, Chengdu, Guangzhou, Harbin, Jining, Nanning, Shanghai
2021-09-30
Active, closed
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
NCT04931654Carcinoma, Non-Small-Cell Lung, Gastric Cancer, Gastroesophageal Junction Cancer
DrugAZD7789
AstraZeneca
Phase 1/2
136
Beijing, Guangzhou
2021-09-28
Active, closed
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05023980Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsPirtobrutinib·Bendamustine·Rituximab
Loxo Oncology, Inc.
Phase 3
309
Hefei, Beijing, Guangzhou, Wuhan, Changsha, Hohhot, Nanchang, Shenyany
2021-09-23
Recruiting
ICCRT vs. CRT for Locally Advanced Nasopharyngeal Carcinoma
NCT05062005Locally Advanced Nasopharyngeal Carcinoma
First Affiliated Hospital, Sun Yat-Sen University
Phase 3
447
Guangzhou
2021-09-22
Active, closed
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
NCT04965493Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsPirtobrutinib·Venetoclax·Rituximab
Loxo Oncology, Inc.
Phase 3
600
Beijing, Changsha, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Hengyang
2021-09-20
Active, closed
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
NCT04557462Primary IgA Nephropathy
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
448
Beijing, Guangzhou, Luoyang, Zhengzhou, Changsha, Changchun, Yinchuan, Taiyuan
2021-09-20
Recruiting
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
NCT04973605Relapsed/Refractory Multiple Myeloma
DrugsSonrotoclax·Carfilzomib·Pomalidomide·Daratumumab
BeOne Medicines
Phase 1/2
246
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan
2021-09-16
Recruiting
Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002)
NCT05098119Oral Cavity Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
DrugSintilimab
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
43
Guangzhou
2021-09-16
Active, closed
Precise Profiling of Liver Disease Patients With DPMAS Therapy, Treating Optimal Patients and Achieving Hard Endpoint (PADSTONE Study)
NCT05129904DPMAS Therapy in Liver Disease Patients
Nanfang Hospital, Southern Medical University
Observational
1,300
Chongqing, Guangzhou, Hebei, Changsha, Nanjing, Xuzhou, Nanchang, Changchun
2021-09-15
Recruiting
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
NCT05006716B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
DrugTacabrutideg
BeOne Medicines
Phase 1/2
645
Beijing, Guangzhou, Zhengzhou, Yichang, Shanghai, Tianjin, Wenzhou
2021-09-13
Active, closed
A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)
NCT04765059Non-small Cell Lung Cancer
DrugCarboplatin
AstraZeneca
Phase 3
98
Beijing, Ganzhou, Guangzhou, Jinan, Shenyang, Tianjin, Zhengzhou
2021-09-12
Active, closed
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
NCT05009836Non-small Cell Lung Cancer
Hutchmed
Phase 3
412
Guangzhou
2021-09-06
Recruiting
MRD Monitoring in Lung Cancer After Resection
NCT04976296Lung Cancer
Guangdong Provincial People's Hospital
Observational
300
Guangzhou
2021-09-01
Active, closed
Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC.
NCT05043688Resectable Esophageal Squamous Cell Carcinoma
DrugCamrelizumab
Zhigang Li
Phase 3
426
Shanghai, Anyang, Guangzhou, Hefei
2021-09-01
Recruiting
S-1 and Oxaliplatin (SOX) Plus Sintilimab in the Locally Advanced Esophagogastric Junction Adenocarcinoma
NCT04989985Locally Advanced Gastroesophageal Junction Adenocarcinoma, Chemotherapy Effect
DrugsTegafur Gimeracil Oteracil·Oxaliplatin
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2
302
Guangzhou
2021-09-01
Not yet open
Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasโ„ข BRS System
NCT04995159Coronary Heart Disease
Lepu Medical Technology (Beijing) Co., Ltd.
Not applicable
2,150
Bengbu, Hefei, Wuhu, Beijing, Chongqing, Lanzhou, Foshan, Guangzhou
2021-09
Active, closed
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
NCT04849728NASH - Nonalcoholic Steatohepatitis
Inventiva Pharma
Phase 3
1,000
Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Shenzhen, Nanning
2021-08-19
Active, closed
A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
NCT04974398Nasopharyngeal Carcinoma
DrugPenpulimab
Akeso
Phase 3
296
Hefei, Fuzhou, Xiamen, Dongguan, Guangzhou, Jiangmen, Shantou, Shenzhen
2021-08-16
Recruiting
Effect of Standard Nutrition Therapy on Nutritional Status and Prognosis in Locoregionally Advanced Nasopharyngeal Carcinoma Patients With Malnutrition
NCT04436965Nasopharyngeal Carcinoma, Nutrition Therapy
DrugCisplatin
Sun Yat-sen University
Phase 3
266
Guangzhou
2021-08-16
Recruiting
Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLC
NCT05011487Non-Small Cell Lung Cancer
DrugsTagrisso·Osimertinib·Pemetrexed·Cisplatin
Sun Yat-sen University
Phase 2
30
Guangzhou
2021-08-13
Recruiting
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2ฮฑ Related Genetic Alterations (MK-6482-015)
NCT04924075Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor
DrugBelzutifan
Merck Sharp & Dohme LLC
Phase 2
355
Beijing, Guangzhou, Shanghai, Chengdu
2021-08-12
Active, closed
Effectivity and Safety of PFO Closure vs Medicine in Alleviating Migraine
NCT04946734PFO - Patent Foramen Ovale, Migraine
Guangdong Provincial People's Hospital
Phase 3
440
Xiamen, Guangzhou, Huizhou, Jiangmen, Shenzhen, Zhanjiang, Nanning, Shangqiu
2021-08-12
Recruiting
Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)
NCT04989621Follicular Lymphoma, Relapsed and Refractory Follicular Lymphoma
Sun Yat-sen University
Phase 2
32
Guangzhou
2021-08-01
By invitation
Chinese Multicenter Clinical Outcome Cohort Study of Myotonic Dystrophy Type 1 (C-DMCOS-DM1)
NCT06101940Myotonic Dystrophy 1
Huashan Hospital
Observational
1,000
Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Wuhan, Nanjing, Suzhou
2021-08-01
Active, closed
PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma
NCT04907370Nasopharyngeal Carcinoma
DrugsGemcitabine·Cisplatin
Sun Yat-sen University
Phase 3
532
Beijing, Chongqing, Foshan, Guangzhou, Nanning, Guiyang, Wuhan, Changsha
2021-08-01
By invitation
Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection
NCT04762459Non-small Cell Lung Carcinoma
DrugsAlmonertinib·Pemetrexed·Cisplatin
Chinese Academy of Medical Sciences
Phase 3
606
Beijing, Changsha, Chendu, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2021-08-01
Recruiting
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
NCT04817618C3G
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
98
Guangzhou, Wuhan, Beijing, Shanghai
2021-07-28
Active, closed
China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
NCT06868654Multiple Myeloma
DrugsBelantamab mafodotin·Bortezomib·Daratumumab·Dexamethasone
GlaxoSmithKline
Phase 3
72
Beijing, Changchun, Guangzhou, Hangzhou, Jinan, Nanjing, Shenyang, Suzhou
2021-07-28
By invitation
A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
NCT04976322Systemic Lupus Erythematosus
UCB Biopharma SRL
Phase 3
760
Beijing, Changchun, Guangzhou, Guilin, Shanghai, Suzhou, Tianjin, Wenzhou
2021-07-27
Active, closed
Newly Diagnosed Glioblastoma
NCT04959500Glioblastoma
DrugsAnlotinib hydrochloride·Temozolomide
Sun Yat-sen University
Phase 2
150
Bengbu, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Shenzhen, Zhuhai
2021-07-21
Active, closed
Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)
NCT05712902Non-Small Cell Lung Cancer
DrugSunvozertinib
Dizal Pharmaceuticals
Phase 2
104
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Haikou, Hangzhou
2021-07-19
Active, closed
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
NCT04961567Lupus Erythematosus, Systemic
DrugLitifilimab
Biogen
Phase 3
562
Beijing, Dongguan, Guangzhou, Shenzhen, Haikou, Changsha, Zhuzhou, Wuhan
2021-07-16
Active, closed
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naรฏve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFฮฑ Inhibitor Treatment
NCT04908189Psoriatic Arthritis
DrugsApremilast·Deucravacitinib
Bristol-Myers Squibb
Phase 3
729
Bengbu, Beijing, Guangzhou, Shenzhen, Zhengzhou, Changsha, Changzhou, Nanjing
2021-07-15
Recruiting
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
NCT04951622Myasthenia Gravis
DrugNipocalimab
Janssen Research & Development, LLC
Phase 3
199
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan
2021-07-15
Active, closed
A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer
NCT04898634Prostatic Neoplasms
DrugPasritamig
Janssen Research & Development, LLC
Phase 1
216
Beijing, Chongqing, Guangzhou, Wenzhou
2021-07-13
Active, closed
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naรฏve to Biologic Disease-modifying Anti-rheumatic Drugs
NCT04908202Psoriatic Arthritis
DrugDeucravacitinib
Bristol-Myers Squibb
Phase 3
670
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Dalian, Shanghai, Yiwu
2021-07-13
Active, closed
Phase II Neoadjuvant Pyrotinib Combined With Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial
NCT05165225Breast Cancer, HER2-low-expressing Breast Cancer, Hormone Receptor-positive Breast Cancer, Neoadjuvant Therapy
DrugPyrotinib
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
48
Guangzhou
2021-07-13
Recruiting
Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002)
NCT04807140Head and Neck Squamous Cell Carcinoma
DrugTislelizumab
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
57
Guangzhou
2021-07-08
Recruiting
A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma
NCT04993690B-cell Lymphoma
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 1
200
Beijing, Guangzhou
2021-07-06
Active, closed
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
NCT04886804Neoplasm Metastasis, Non-Small Cell Lung Cancer
DrugZongertinib
Boehringer Ingelheim
Phase 1
554
Beijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Nanning, Shanghai
2021-07-02
Active, closed
A Study of SHR-A1904 in Patients With Advanced Solid Cancer
NCT04877717Advanced Solid Cancer
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1
107
Guangzhou
2021-07-01
Not yet open
An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC
NCT04890522Nasopharyngeal Carcinoma, Metastasis, Chemotherapy, Immunotherapy
DrugsGemcitabine·Cisplatin·Tislelizumab·Bevacizumab
Sun Yat-sen University
Phase 2/3
622
Guangzhou
2021-07-01
Recruiting
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
NCT04900818Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer
DrugGivastomig
I-Mab Biopharma US Limited
Phase 1
330
Hefei, Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Shenyang, Shanghai
2021-06-29
Active, closed
Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer
NCT04725994Gastric Cancer
DrugsXelox·Irinotecan
Idience Co., Ltd.
Phase 1/2
87
Beijing, Guangzhou, Shanghai
2021-06-28
Active, closed
A Study of TQ05105 in Patients With Chronic Graft Versus Host Disease
NCT04944043Chronic Graft Versus Host Disease
DrugRovadicitinib
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
45
Hefei, Guangzhou, Nanning, Shijiazhuang, Zhengzhou, Wuhan, Suzhou, Tianjin
2021-06-25
Active, closed
A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy
NCT04629248Primary Membranous Nephropathy
DrugsDiphenhydramine·Acetaminophen·Tacrolimus·Methylprednisolone
Hoffmann-La Roche
Phase 3
142
Hangzhou, Beijing, Chengdu, Fuzhou, Guangzhou, Shanghai, Wuhan, Xi'an
2021-06-25
Active, closed
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
NCT04793958Advanced Colorectal Cancer, Metastatic Colorectal Cancer
DrugsMRTX849·Erbitux·MFOLFOX6·Folfiri
Mirati Therapeutics Inc.
Phase 3
461
Bengbu, Hefei, Beijing, Fuzhou, Guangzhou, Shenzhen, Nanning, Zhengzhou
2021-06-24
Active, closed
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)
NCT05171816Metastatic Castration-resistant Prostate Cancer
DrugsAbiraterone acetate·Olaparib
AstraZeneca
Phase 3
110
Beijing, Chongqing, Guangzhou, Guizhou, Henan, Hubei, Hunan, Jilin City
2021-06-24
Recruiting
A Prospective Multicenter Clinical Study of SCCG Protocol and ctDNA 5hmc in Predicting the Chemotherapy Sensitivity and Monitoring the Recurrence and Metastasis of Hepatoblastoma in Children and Adolescents
NCT07300449Hepatoblastoma
Sun Yat-sen University
Phase 2
100
Guangzhou
2021-06-23
Recruiting
A Study of Toripalimab as Consolidation Therapy After Postoperative Chemoradiotherapy in HNSCC
NCT04992559Head and Neck Squamous Cell Carcinomas
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
41
Guangzhou
2021-06-22
Recruiting
Omics Sequencing of Specimen Derived From Mother-Infant-Pairs
NCT05462366Healthy, Breast-milk Collection, Feces
Zhujiang Hospital
Observational
100
Guangzhou
2021-06-22
Active, closed
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
NCT04895358Breast Neoplasms
DrugsXeloda·Liposomal doxorubicin·Abraxane·Nab-paclitaxel
Merck Sharp & Dohme LLC
Phase 3
342
Hefei, Beijing, Xiamen, Foshan, Guangzhou, Shenzhen, Nanning, Zhengzhou
2021-06-18
Recruiting
Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
NCT04790305Carcinoma Breast, Triple-negative Breast Cancer, Invasive Ductal Carcinoma, Breast
Fudan University
Phase 4
1,072
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Harbin, Zhengzhou
2021-06-18
Rows per page Showing 2801–2900 of 3318
Previous 27 28 29 30 31 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/guangzhou?page=29

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 3,318 of those studies with a site in Guangzhou.

How many clinical trials are recruiting in Guangzhou?

1,972 of the 3,318 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 473 have not yet opened recruitment, 805 are active but closed to new participants, and 68 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.